All In Biotech

Drug Trial Radar · NCT07942168

Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma

Phase II Randomized Trial of Doxorubicin Plus Dacarbazine Versus Standard Doxorubicin as First-Line Therapy for Metastatic Uterine Leiomyosarcoma or t Uterine Leiomyosarcoma Recurrent After Surgical Treatment

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 24, 2023

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Blokhin's Russian Cancer Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.

Conditions

  • Leiomyosarcoma
  • Uterine Leiomyosarcoma

Interventions

  • DoxorubicinDrug

    Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line

  • DoxorubicinDrug

    Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

  • dacarbazineDrug

    Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1-year progression-free survival (PFS)Time frame: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)

    Moscow, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.